166 related articles for article (PubMed ID: 31848332)
21. Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11
Sakamoto S; Matsueda S; Takamori S; Toh U; Noguchi M; Yutani S; Yamada A; Shichijo S; Yamada T; Suekane S; Kawano K; Naitou M; Sasada T; Hattori N; Kohno N; Itoh K
Cancer Sci; 2017 Apr; 108(4):598-603. PubMed ID: 28178396
[TBL] [Abstract][Full Text] [Related]
22. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
[TBL] [Abstract][Full Text] [Related]
23. [Specific anti-glioma angiogenesis immune response induced by attenuated Salmonella typhimurium vaccine expressing vascular endothelial growth factor receptor-2].
Feng KK; Zhao HY; Qiu H; Chen J
Ai Zheng; 2005 May; 24(5):548-53. PubMed ID: 15890095
[TBL] [Abstract][Full Text] [Related]
24. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features.
La Rosa S; Uccella S; Finzi G; Albarello L; Sessa F; Capella C
Hum Pathol; 2003 Jan; 34(1):18-27. PubMed ID: 12605362
[TBL] [Abstract][Full Text] [Related]
25. Multiple therapeutic peptide vaccines for patients with advanced gastric cancer.
Fujiwara Y; Okada K; Omori T; Sugimura K; Miyata H; Ohue M; Kobayashi S; Takahashi H; Nakano H; Mochizuki C; Shimizu K; Yano M; Nakamura Y; Mori M; Doki Y
Int J Oncol; 2017 May; 50(5):1655-1662. PubMed ID: 28393243
[TBL] [Abstract][Full Text] [Related]
26. Significant clinical response of advanced colon cancer to peptide vaccine therapy: a case report.
Yasuda S; Tsuchiya I; Okada K; Tanaka A; Suzuki T; Sadahiro S; Takeda K; Yamamoto S; Nakui M
Tokai J Exp Clin Med; 2012 Jul; 37(2):57-61. PubMed ID: 22763829
[TBL] [Abstract][Full Text] [Related]
27. Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer.
Hasegawa K; Ikeda Y; Kunugi Y; Kurosaki A; Imai Y; Kohyama S; Nagao S; Kozawa E; Yoshida K; Tsunoda T; Nakamura Y; Fujiwara K
J Immunother; 2018 May; 41(4):201-207. PubMed ID: 29432282
[TBL] [Abstract][Full Text] [Related]
28. Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas.
Saito K; Kato M; Susaki N; Nagatani T; Nagasaka T; Yoshida J
Clin Neuropathol; 2003; 22(1):30-4. PubMed ID: 12617191
[TBL] [Abstract][Full Text] [Related]
29. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation.
Dikov MM; Ohm JE; Ray N; Tchekneva EE; Burlison J; Moghanaki D; Nadaf S; Carbone DP
J Immunol; 2005 Jan; 174(1):215-22. PubMed ID: 15611243
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
Sun S; Liu A
J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
[TBL] [Abstract][Full Text] [Related]
31. IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides.
Kanekiyo S; Hazama S; Takenouchi H; Nakajima M; Shindo Y; Matsui H; Tokumitsu Y; Tomochika S; Tsunedomi R; Tokuhisa Y; Iida M; Sakamoto K; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Okuno K; Udaka K; Kawakami Y; Matsueda S; Ito K; Nagano H
Oncol Rep; 2018 May; 39(5):2385-2392. PubMed ID: 29498403
[TBL] [Abstract][Full Text] [Related]
32. [Expressions of VEGF/VEGFRs and activation of STATs in ovarian carcinoma].
Chen BY; Ye DF; Xie X; Chen HZ; Lü WG
Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):33-7. PubMed ID: 15771796
[TBL] [Abstract][Full Text] [Related]
33. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
[TBL] [Abstract][Full Text] [Related]
34. A novel recombinant anti-epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model.
Asadi-Ghalehni M; Rasaee MJ; RajabiBazl M; Khosravani M; Motaghinejad M; Javanmardi M; Khalili S; Modjtahedi H; Sadroddiny E
Microbiol Immunol; 2017 Dec; 61(12):531-538. PubMed ID: 29023946
[TBL] [Abstract][Full Text] [Related]
35. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports.
Goutagny S; Kalamarides M
Neurochirurgie; 2018 Nov; 64(5):370-374. PubMed ID: 28162254
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
Ishizaki H; Tsunoda T; Wada S; Yamauchi M; Shibuya M; Tahara H
Clin Cancer Res; 2006 Oct; 12(19):5841-9. PubMed ID: 17020992
[TBL] [Abstract][Full Text] [Related]
37. Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.
Ouerdani A; Goutagny S; Kalamarides M; Trocóniz IF; Ribba B
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1263-73. PubMed ID: 27146400
[TBL] [Abstract][Full Text] [Related]
38. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G
Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692
[TBL] [Abstract][Full Text] [Related]
39. Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.
Vreeland TJ; Litton JK; Qiao N; Philips AV; Alatrash G; Hale DF; Jackson DO; Peace KM; Greene JM; Berry JS; Clifton GT; Peoples GE; Mittendorf EA
Clin Immunol; 2018 Jul; 192():6-13. PubMed ID: 29574039
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma.
Nasir A; Reising LO; Nedderman DM; Fulford AD; Uhlik MT; Benjamin LE; Schade AE; Holzer TR
Anticancer Res; 2016 Jun; 36(6):2683-96. PubMed ID: 27272777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
